Responses

PDF
Original article
Simultaneous intravitreal injection of triamcinolone acetonide and tissue plasminogen activator for central retinal vein occlusion: a pilot study
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Tissue plasminogen activator (tPA) and retinal vein occlusion

    Dear editor:

    Yamamoto and coworkers present in their paper the effect of simultaneous intravitreal injection of a mixture of 4mg triamcinolone acetonide (TA) and 25?g tissue plasminogen activator (tPA) to treat macular edema due to central retinal vein occlusion (CRVO) ?1?. The authors included 20 eyes. Best corrected visual acuity (BCVA) improved three lines or more in 65%, 55%, 55% and 53% of eyes and the mea...

    Show More
    Conflict of Interest:
    None declared.